Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 4/20 | 0.42 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.37 |
| ▸ | ULK1 | O75385 | 2/20 | 0.37 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997676 | 1.00 | WEE1 (0.42) | WEE1PKMYT1LRRK2TNK2SYK | |
| SCHEMBL30997635 | 0.89 | WEE1 (0.49) | WEE1PKMYT1TNK2SYKJAK2 | |
| SCHEMBL29310208 | 0.89 | WEE1 (0.49) | WEE1PKMYT1TNK2SYKJAK2 | |
| SCHEMBL30997621 | 0.89 | PKMYT1 (0.49) | WEE1PKMYT1LRRK2TNK2SYK | |
| SCHEMBL29310217 | 0.89 | PKMYT1 (0.49) | WEE1PKMYT1LRRK2TNK2SYK | |
| SCHEMBL29310236 | 0.82 | BTK (0.49) | WEE1PKMYT1TNK2SYKSLC2A1 | |
| SCHEMBL29310230 | 0.82 | WEE1 (0.48) | WEE1TNK2SYKSLC2A1ULK1 | |
| SCHEMBL30997622 | 0.80 | SLC2A1 (0.57) | WEE1PKMYT1LRRK2TNK2JAK2 | |
| SCHEMBL29310117 | 0.80 | SLC2A1 (0.57) | WEE1PKMYT1LRRK2TNK2JAK2 | |
| SCHEMBL30997606 | 0.80 | MAP4K1 (0.39) | WEE1LRRK2SYKSLC2A1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | WEE1 1/4885PKMYT1 1740/4885LRRK2 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.